ABSTRACT
Introduction: Pterygium progression and recurrence is acommon complication. In various studies conducted on role ofsubconjunctival depot injection of bevacizumab, nothing hasbeen standardized with regards to dosage and its frequency.The study was done with aim to assess role and clinicalefficacy of subconjunctival injection of bevacizumab as a nonsurgical treatment modality for pterygium.Material and Methods: 80 cases of pterygium were includedin this study. Study was done over a period of 12 months fromDecember 2018 to November 2019 at a tertiary care ophthalmiccentre of Northern India. In this study, three doses of 2.5 mgof bevacizumab were administered sub-conjunctivally atmonthly interval under topical anaesthesia on Outdoor PatientDepartment basis. Standard aseptic measures were observed.Results: Cases were followed up next day after each injectionand thereafter on monthly basis for three months and finallyafter 06 months of first injection. Progression of pterygiumwas noted in 8 cases. Subconjunctival haemorrhage was notedin 41 cases. Conjunctival cyst was seen in three cases whichwere punctured in OPD, however recurrence was noted afterone month in one case. No rise in Intra Ocular Pressure (IOP)was noted.Conclusions: Subconjunctival injection of bevacizumab isuseful in treatment of patients with pterygium without local orsystemic adverse effects.
ABSTRACT
Background: Computer Related Musculoskeletal disorders and Vision Syndrome (CRMSKVS) is defined as symptoms due to prolonged use of Visual Display Terminal (VDT).Methods: A cross-sectional observational study was done among office-workers working on computer terminal. A self-reported questionnaire was distributed and Musculoskeletal (MSK) and visual symptoms in the preceding 12 months (01 October 2017 to 30 September 2018) were taken as dependent variable. Multivariate analysis was done to identify the determinants of CRMSKVS.Results: Responses from 1193 subjects were included in the study. CRMSKVS was present in 489 cases (40.98%; males - 37.5%, females - 58.29%). The main MSK symptoms were pain/stiffness in neck (40.98%), shoulder (38.99%), lower back (35.6%) and elbow/wrist/hand/fingers (23.1%). The ocular symptoms were excessive watering (39.6%), pain (24.99), irritation (18.6%), burning/itching sensation (29.8%), redness (40.7%), blurring of vision (13.2%) and headache (40.9%). Female gender (OR-1.498(1.262-1.778)), long duration of working hours (OR-2.77(2.399-3.214)), poor break duration (OR-2.59(2.172-3.089)), excessive smart phone use (OR-2.071(1.834-2.338)), poor posture (OR-3.883(3.282-4.592)), inappropriate distance of computer screen (OR-2.173(1.829-2.582)), low height of screen (OR-1.936(1.527-2.454)), distance of keyboard (OR-3.161(2.528-3.953)) and distance of mouse (OR-5.785(3.932-8.512)) were identified as significant determinants of CRMSKVS.Conclusions: CRMSKVS is an emerging pandemic which needs urgent attention by medical and administrative authorities. The device factors, personal factors, environmental and ergonomic factors are the modifiable risk factors for CRMSKVS.